Spur Ventures II, LP 4
4 · CONSTELLATION PHARMACEUTICALS INC · Filed Jul 23, 2018
Insider Transaction Report
Form 4
Spur Ventures II, LP
10% Owner
Transactions
- Conversion
Common Stock
2018-07-23+349,853→ 349,853 total - Conversion
Series E Preferred Stock
2018-07-23−888,888→ 0 total→ Common Stock (103,811 underlying) - Conversion
Series E-1 Preferred Stock
2018-07-23−1,208,678→ 0 total→ Common Stock (109,788 underlying) - Conversion
Series F Preferred Stock
2018-07-23−1,500,000→ 0 total→ Common Stock (136,254 underlying)
Footnotes (2)
- [F1]On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.
- [F2]The securities are directly held by Spur Ventures II, L.P., and indirectly held by Spur Capital Partners, LLC, the manager of Spur Ventures II, L.P. Spur Capital Management II, LLC is the general partner of Spur Ventures II, L.P. Spur Capital Partners, LLC may be deemed to have voting and investment power with respect to such shares.